IACH Focus on Leukemia 2020 | Highlights in leukemia research: MRD as a prognostic factor
Arnon Nagler
• 5 Oct 2020
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the importance of measurable residual disease (MRD). In recent years, MRD has been used as a prognostic factor in acute lymphoblastic leukemia (ALL). However, in acute myeloid leukemia (AML), MRD negativity is harder to achieve. There have been other signs of progress in chronic leukemias, such as the use of ibrutinib and venetoclax. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
